Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice.

Lilly said that the company had completed the $800 million Kinsale factory expansion project to increase the production of its obesity and diabetes drugs Mounjaro and Zepbound. At the same time, the pharmaceutical company will also invest $1 billion to build a factory in Limerick to increase the production of biopharmaceutical raw materials, especially Kisunla, a drug approved by the FDA to treat Alzheimer's disease two months ago. The production of active pharmaceutical ingredients is expected to begin in 2026.

Lilly stated that Limerick's expansion will add tools for artificial intelligence, automated robots, and machine learning to the website. It will also add about 150 new positions, including scientists, engineers, and operators, bringing the total number of employees in the factory to 450. Construction requires planning approval, and Lilly Plan will submit the application soon.
In fact, Lilly has already made significant investments in Limerick, with the latest one being in August last year, investing $500 million and adding 300 new jobs. In January 2022, Eli Lilly invested $446 million to expand the production of active pharmaceutical ingredients and monoclonal antibodies. The company stated that it has spent $2 billion on this factory so far.
Lilly and its competitor Novo Nordisk have been competing to promote their respective GLP-1 production. Lilly has been working hard to increase production capacity, building a $5.2 billion factory in its hometown of Indiana to produce raw materials for tirzepatide, and acquiring a sterile injection site from Nexus Pharma.
Novo Nordisk has previously stated that it is also considering expanding its business in Ireland after acquiring land outside of Dublin. But afterwards, Novo turned around and allocated $4.1 billion to build a new factory in Clayton, North Carolina.
Other pharmaceutical companies are also seeking to increase production capacity in Ireland.
In September 2023, Astellai announced that the company had allocated 330 million euros (364 million US dollars) to establish a new base in Tralee. In 2022, Pfizer announced that it will invest nearly $1 billion in its Dublin factory. AstraZeneca also budgeted $360 million in 2021 to build its first Irish factory.